Seres Therapeutics to Present at the 2016 UBS Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced it will present at the UBS Global Healthcare Conference on Tuesday, May 24. The presentation will take place at the Grand Hyatt Hotel in New York, NY at 8:30 a.m. ET.

Live audio webcast will be available under the Investors and Media section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring Clostridium difficile infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres’ second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160517005598/en/

IR and PR Contact:
Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
[email protected]

Source: Seres Therapeutics

You May Also Be Interested In

• LayerZero (ZRO) Has Deployed $112M Into Buybacks, Next Crypto To Explode Could Be AlphaPepe With $2.5M Raised
• Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
• SOUEAST C-DM Hybrid System: Adapting to Urban and Intercity Travel Needs